These results strengthen the already known benefits of SGLT2 inhibitors in reducing the risk for HF hospitalization and cardiovascular death in patients with HFrEF as well as in high-risk groups, those with type 2 diabetes or chronic kidney disease. Here, SLC5A2 is linked to chronic kidney disease.